Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies
Open Access

Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model

TSUBASA GOSHIMA, KATSUAKI IEGUCHI, NOBUYUKI ONISHI, TAKASHI SHIMIZU, DAISUKE TAKAYANAGI, MAKOTO WATANABE, YUKI FUJIMOTO, RYOTARO OHKUMA, RISAKO SUZUKI, TOSHIAKI TSURUI, EMIKO MURA, NANA IRIGUCHI, TOMOYUKI ISHIGURO, MASAHIRO SHIMOKAWA, YUYA HIRASAWA, YUTARO KUBOTA, HIROTSUGU ARIIZUMI, ATSUSHI HORIIKE, KIYOSHI YOSHIMURA, MAYUMI TSUJI, YUJI KIUCHI, SHINICHI KOBAYASHI, JUN FUJISHIRO, ROBERT M. HOFFMAN, TAKUYA TSUNODA and SATOSHI WADA
Anticancer Research January 2024, 44 (1) 23-29; DOI: https://doi.org/10.21873/anticanres.16784
TSUBASA GOSHIMA
1Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
3Department of Pediatric Surgery, The University of Tokyo Hospital, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATSUAKI IEGUCHI
1Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
4Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NOBUYUKI ONISHI
1Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
4Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKASHI SHIMIZU
1Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
4Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAISUKE TAKAYANAGI
1Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
4Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAKOTO WATANABE
1Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
4Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
5Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan;
6Pharmacological Research Center, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKI FUJIMOTO
1Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
4Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYOTARO OHKUMA
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RISAKO SUZUKI
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOSHIAKI TSURUI
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
5Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan;
6Pharmacological Research Center, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EMIKO MURA
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NANA IRIGUCHI
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMOYUKI ISHIGURO
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAHIRO SHIMOKAWA
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUYA HIRASAWA
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUTARO KUBOTA
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROTSUGU ARIIZUMI
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ATSUSHI HORIIKE
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KIYOSHI YOSHIMURA
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
4Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
7Department of Clinical ImmunoOncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAYUMI TSUJI
6Pharmacological Research Center, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUJI KIUCHI
5Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan;
6Pharmacological Research Center, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINICHI KOBAYASHI
4Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUN FUJISHIRO
3Department of Pediatric Surgery, The University of Tokyo Hospital, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ROBERT M. HOFFMAN
8AntiCancer Inc., San Diego, CA, U.S.A.;
9Department of Surgery, University of California, San Diego, CA, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKUYA TSUNODA
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SATOSHI WADA
1Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
4Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: st-wada{at}med.showa-u.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 44 no. 1 23-29
DOI 
https://doi.org/10.21873/anticanres.16784
PMID 
38159965

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received October 19, 2023
  • Revision received November 16, 2023
  • Accepted November 17, 2023
  • Published online December 30, 2023.

Copyright & License 
Copyright © 2024 The Author(s). Published by the International Institute of Anticancer Research. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

Author Information

  1. TSUBASA GOSHIMA1,2,3,
  2. KATSUAKI IEGUCHI1,4,
  3. NOBUYUKI ONISHI1,4,
  4. TAKASHI SHIMIZU1,4,
  5. DAISUKE TAKAYANAGI1,2,4,
  6. MAKOTO WATANABE1,4,5,6,
  7. YUKI FUJIMOTO1,2,4,
  8. RYOTARO OHKUMA2,
  9. RISAKO SUZUKI2,
  10. TOSHIAKI TSURUI2,5,6,
  11. EMIKO MURA2,
  12. NANA IRIGUCHI2,
  13. TOMOYUKI ISHIGURO2,
  14. MASAHIRO SHIMOKAWA2,
  15. YUYA HIRASAWA2,
  16. YUTARO KUBOTA2,
  17. HIROTSUGU ARIIZUMI2,
  18. ATSUSHI HORIIKE2,
  19. KIYOSHI YOSHIMURA2,4,7,
  20. MAYUMI TSUJI6,
  21. YUJI KIUCHI5,6,
  22. SHINICHI KOBAYASHI4,
  23. JUN FUJISHIRO3,
  24. ROBERT M. HOFFMAN8,9,
  25. TAKUYA TSUNODA2 and
  26. SATOSHI WADA1,2,4⇑
  1. 1Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
  2. 2Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan;
  3. 3Department of Pediatric Surgery, The University of Tokyo Hospital, Tokyo, Japan;
  4. 4Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
  5. 5Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan;
  6. 6Pharmacological Research Center, Showa University, Tokyo, Japan;
  7. 7Department of Clinical ImmunoOncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;
  8. 8AntiCancer Inc., San Diego, CA, U.S.A.;
  9. 9Department of Surgery, University of California, San Diego, CA, U.S.A.
  1. Correspondence to: Professor Dr. Satoshi Wada, Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan. Tel: +81 333005257, Fax: +81 333001653, e-mail: st-wada{at}med.showa-u.ac.jp
View Full Text

Statistics from Altmetric.com

Cited By...

  • 3 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research: 44 (1)
Anticancer Research
Vol. 44, Issue 1
January 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model
TSUBASA GOSHIMA, KATSUAKI IEGUCHI, NOBUYUKI ONISHI, TAKASHI SHIMIZU, DAISUKE TAKAYANAGI, MAKOTO WATANABE, YUKI FUJIMOTO, RYOTARO OHKUMA, RISAKO SUZUKI, TOSHIAKI TSURUI, EMIKO MURA, NANA IRIGUCHI, TOMOYUKI ISHIGURO, MASAHIRO SHIMOKAWA, YUYA HIRASAWA, YUTARO KUBOTA, HIROTSUGU ARIIZUMI, ATSUSHI HORIIKE, KIYOSHI YOSHIMURA, MAYUMI TSUJI, YUJI KIUCHI, SHINICHI KOBAYASHI, JUN FUJISHIRO, ROBERT M. HOFFMAN, TAKUYA TSUNODA, SATOSHI WADA
Anticancer Research Jan 2024, 44 (1) 23-29; DOI: 10.21873/anticanres.16784

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model
TSUBASA GOSHIMA, KATSUAKI IEGUCHI, NOBUYUKI ONISHI, TAKASHI SHIMIZU, DAISUKE TAKAYANAGI, MAKOTO WATANABE, YUKI FUJIMOTO, RYOTARO OHKUMA, RISAKO SUZUKI, TOSHIAKI TSURUI, EMIKO MURA, NANA IRIGUCHI, TOMOYUKI ISHIGURO, MASAHIRO SHIMOKAWA, YUYA HIRASAWA, YUTARO KUBOTA, HIROTSUGU ARIIZUMI, ATSUSHI HORIIKE, KIYOSHI YOSHIMURA, MAYUMI TSUJI, YUJI KIUCHI, SHINICHI KOBAYASHI, JUN FUJISHIRO, ROBERT M. HOFFMAN, TAKUYA TSUNODA, SATOSHI WADA
Anticancer Research Jan 2024, 44 (1) 23-29; DOI: 10.21873/anticanres.16784
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Combination of 3-(Trihydroxygermyl)propanoic Acid (THGP) and Lipopolysaccharide Promotes Macrophage Differentiation to M1, and Antitumor Activity
  • Loss of Trefoil Factor 1 Accelerates the Immune Response to Colorectal Cancer
  • Google Scholar

More in this TOC Section

  • Low-dose Andrographolide Synergizes With Cytarabine or Vincristine in Plasma Cell Neoplasm Cell Lines
  • Enzalutamide Enhanced Honokiol-induced Apoptotic Insults to Drug-resistant Glioblastoma Cells via an Intrinsic Bak-mitochondrion-caspase Cascade Mechanism
  • Milk Extracellular Vesicle–mediated Delivery of siPRNP Suppresses Growth and Wound Closure in PC-3M Prostate Cancer Cells
Show more Experimental Studies

Keywords

  • immune checkpoint inhibitor
  • non-classical monocyte
  • flow cytometry
  • overall survival
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire